Tryptoline urea derivatives for sensitizing resistant breast cancer cells to doxorubicin.
Co-administration of compound 9 with doxorubicin (DOX) significantly reduced fold resistance in MCF-7/DXR cells, almost restoring their sensitivity to levels similar to the parental cell line, and compound 9 acted synergistically with DOX, markedly increasing its cytotoxicity, associated with a strong increase in apopt...